Table 3.
Cox Proportional Hazard Model for Clinical Relapse in Patients with HBsAg Level ≥100 IU/mL (n=91)
| Variable | Univariate Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age (years) | 1.039 | 0.997–1.098 | 0.07 | 1.029 | 0.985–1.074 | 0.103 |
| Male vs Female | 1.107 | 0.527–2.326 | 0.789 | |||
| First-line vs Second-line drugs† | 0.911 | 0.487–1.704 | 0.711 | |||
| Treatment duration (years) | 1.108 | 0.975–1.259 | 0.117 | 1.134 | 0.986–1.258 | 0.102 |
| Consolidation treatment duration (years) | 1.092 | 0.981–1.215 | 0.106 | 0.754 | 0.586–0.971 | 0.029 |
| ALT (U/L) | 0.974 | 0.940–1.010 | 0.158 | 0.968 | 0.929–1.008 | 0.118 |
| HBsAg (log10 IU/mL) | 0.723 | 0.379–1.379 | 0.324 | |||
| HBcrAg (log10 U/mL) | 2.060 | 1.383–3.068 | <0.001 | 2.102 | 1.422–3.107 | <0.001 |
| ≥4.0 log10 U/mL | 4.202 | 2.082–8.482 | <0.001 | |||
| <4.0 log10 U/mL | Ref | |||||
Notes: †First-line, entecavir, tenofovir; second-line, lamivudine, adefovir, telbivudine, and combination treatment.
Abbreviations: ALT, alanine aminotransferase; ULN, upper limit of normal; HBeAg, hepatitis B envelope antigen; HBsAg, hepatitis B surface antigen; HBcrAg, hepatitis B core-relative antigen; ns, no significance; HR, hazard ratio; 95% CI, 95% confidence interval.